久久久久国产一区二区三区,97国产3,77777色熟女,午夜欧美巨大性欧美巨大

  設為主頁 加入收藏 English
 
 
 
 新聞動態(tài)
 行業(yè)動態(tài)
 展會信息
 誠聘英才
 
 

測量應用案例-20210403

發(fā)布時間:2021-05-18  點擊次數(shù):355  新聞來源:
 

文獻名:Eradicating intracellular MRSA via targeted delivery of lysostaphin and vancomycin with mannose-modified exosomes

 

 

作者Xiaohong Yangab; Beibei Xieb; Haibo Pengb; Gongming Shib; Banne Sreenivasb; Jian Guob; Chenhui Wangb; Yun Heb

a  Chongqing Institute of Green and Intelligent Technology, Chinese Academy of Sciences, 266 Fangzheng Ave, Shuitu Technology Development Zone, Beibei, 400714 Chongqing, China

b  Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, 55 Daxuecheng South Road, Shapingba, 401331 Chongqing, China

 

 

 

摘要:Intracellular methicillin-resistant Staphylococcus aureus (MRSA) is extremely difficult to remove by common antibiotics, leading to infection recurrence and resistance. Herein we report a novel exosome-based antibiotic delivery platform for eradicating intracellular MRSA, where mannosylated exosome (MExos) is employed as the drug carrier and preferentially taken up by macrophages, delivering lysostaphin (MExoL) and vancomycin (MExoV) to intracellular pathogens. Combination of MExoL and MExoV eradicated intracellular quiescent MRSA. Moreover, MExos rapidly accumulated in mouse liver and spleen, the target organs of intracellular MRSA, after intravenous (IV) administration. Thus, the MExos antibiotic delivery platform is a promising strategy for combating intracellular infection.

 

 

關鍵詞:Exosomes; Surface functionalization; Antibiotics; Targeted delivery; Intracellular infection

 

 
 
上海市普陀區(qū)嵐皋路567號1108-26室 電話:021-62665073 400-718-7758 傳真:021-62761957
美國布魯克海文儀器公司上海代表處 版權所有  管理登陸 ICP備案號:滬ICP備19006074號-2 技術支持:化工儀器網(wǎng)